- Previous Close
16.50 - Open
16.40 - Bid 16.35 x 150000
- Ask 16.55 x 75500
- Day's Range
16.20 - 16.75 - 52 Week Range
10.15 - 22.40 - Volume
6,339 - Avg. Volume
13,254 - Market Cap (intraday)
315.53M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
18.11 - EPS (TTM)
0.90 - Earnings Date Nov 19, 2024
- Forward Dividend & Yield 0.50 (3.03%)
- Ex-Dividend Date Jul 18, 2024
- 1y Target Est
28.00
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. It operates in two segments, Beauty and Trade. The Beauty segment provides aesthetic surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin. This segment also manages a private clinic for plastic and aesthetic surgery; and medical specialist centers for aesthetic and plastic medicine under the Schlossklinik and M1 Med Beauty names. The Trade segment sells pharmaceuticals and medical products for various therapeutic areas comprising oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company was incorporated in 2007 and is based in Berlin, Germany. M1 Kliniken AG is a subsidiary of MPH Health Care AG.
www.m1-kliniken.de219
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: M12.DE
View MorePerformance Overview: M12.DE
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: M12.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: M12.DE
View MoreValuation Measures
Market Cap
315.58M
Enterprise Value
302.59M
Trailing P/E
18.33
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.95
Price/Book (mrq)
2.89
Enterprise Value/Revenue
0.91
Enterprise Value/EBITDA
9.63
Financial Highlights
Profitability and Income Statement
Profit Margin
5.03%
Return on Assets (ttm)
6.72%
Return on Equity (ttm)
12.80%
Revenue (ttm)
333.27M
Net Income Avi to Common (ttm)
16.76M
Diluted EPS (ttm)
0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
10.27M
Total Debt/Equity (mrq)
15.47%
Levered Free Cash Flow (ttm)
23.85M